Mayo Clinic Hematologists Discuss the Latest Treatment Options on OMedLive.com
BOSTON, MA (PRWEB) APRIL 12, 2016
Survival and remission rates for multiple myeloma continue to climb as researchers and clinicians apply the latest research to patient treatment plans. With large conferences like ASCO still months away, it’s important to get timely updates on the latest treatment options for Multiple Myeloma.
Shaji Kumar, MD and David Dingli, MD, both Professors of Medicine, Hematology, at the Mayo Clinic in Rochester, Minnesota, will review the latest treatment practices at a one-hour online CME program hosted by OMedLive.com.
Attendees will learn the newest advances in treating relapsed/refractory multiple myeloma including:
The efficacy and safety of new and emerging agents, prognostic factors and patient-specific clinical criteria for treatment strategy selection, therapeutic implications of combination regimens involving emerging agents with currently available treatment options, timing of treatment initiation and genetic profiling based on disease characteristics and individual patient profiles.
“The therapy of multiple myeloma is evolving with the recent approval of several novel classes of agents: it is important that the role and impact of these exciting agents on the disease as well as specific toxicities are understood.” David Dingli, MD
We recommend this CME program for hematologists, oncologists, internal medicine physicians, family medicine/primary care physicians, and other clinicians who care for patients multiple myeloma, a rare form of cancer affecting about 0.7% of cancer cases overall.
The online CME session will take place April 13th, 11 am – Noon EST at OMedLive.com. This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Bristol-Myers Squibb, and Karyopharm Therapeutics, Inc.
CEO Robert Rosenbloom said, “we’re pleased to deliver this program on Multiple Myeloma ahead of the ASCO conference so clinicians can immediately expand their treatment options for patients. The life expectancy from the diagnosis of Multiple Myeloma increased from three months to four years over the past decade. We hope programs like this can increase it even further.”
One of the unique aspects of OMedLive’s online learning platform is the ability for attendees to ask direct questions to the experts about multiple myeloma. The physicians will be replying to questions throughout the presentation. Attendees can also give their opinion on best medical practices via polling questions throughout the session.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and PlatformQ Health Education. The University of Nebraska Medical Center, Center for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.
- Learn more about this program.
- To speak with one of our panelists about this program contact Christian Rubio, Director of Marketing.